Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Bristol-Myers Squibb Company



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.6%. By the end of trading, Bristol-Myers Squibb Company fell $0.58 (-1.3%) to $44.61 on light volume. Throughout the day, 4,931,582 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10,686,300 shares. The stock ranged in price between $44.51-$45.39 after having opened the day at $45.21 as compared to the previous trading day's close of $45.19. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 35.9%,

Sarepta Therapeutics



), down 18.9%,




), down 15.6% and

OncoMed Pharmaceuticals



), down 12.2%.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $73.9 billion and is part of the health care sector. Shares are up 38.1% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates

Bristol-Myers Squibb Company

as a


. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front,




), up 14.5%,

ImmunoCellular Therapeutics



), up 13.0%,

Transition Therapeutics



), up 11.8% and




), up 10.6% , were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.